Real-time Estimate
Tradegate
06:05:43 2024-07-17 am EDT
|
5-day change
|
1st Jan Change
|
5.635
EUR
|
+0.99%
|
|
+6.38%
|
+25.42%
|
Fiscal Period: März |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
2027
|
---|
Capitalization
1 |
1,473
|
2,314
|
1,070
|
321.6
|
323.4
|
461.5
|
-
|
-
|
Enterprise Value (EV)
1 |
1,842
|
2,292
|
858.3
|
248.3
|
323.4
|
314.5
|
334.5
|
344.5
|
P/E ratio
|
-0.45
x
|
-2.85
x
|
-0.62
x
|
-1.52
x
|
-3.9
x
|
-18.2
x
|
-66.4
x
|
-60.4
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
5.28
x
|
9.43
x
|
4.83
x
|
1.84
x
|
1.2
x
|
1.53
x
|
1.35
x
|
1.24
x
|
EV / Revenue
|
6.6
x
|
9.34
x
|
3.88
x
|
1.42
x
|
1.2
x
|
1.04
x
|
0.98
x
|
0.92
x
|
EV / EBITDA
|
-8.97
x
|
-20.1
x
|
-16.8
x
|
-44.1
x
|
25.4
x
|
19.1
x
|
9.6
x
|
7.41
x
|
EV / FCF
|
-2.66
x
|
-8.69
x
|
-6.04
x
|
-1.94
x
|
-
|
-12.1
x
|
19.9
x
|
-
|
FCF Yield
|
-37.6%
|
-11.5%
|
-16.6%
|
-51.5%
|
-
|
-8.24%
|
5.04%
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
9,741
|
19,798
|
21,477
|
34,213
|
54,539
|
54,549
|
-
|
-
|
Reference price
2 |
151.2
|
116.9
|
49.80
|
9.400
|
5.930
|
8.460
|
8.460
|
8.460
|
Announcement Date
|
9/22/20
|
9/27/21
|
9/20/22
|
6/14/23
|
6/20/24
|
-
|
-
|
-
|
Fiscal Period: März |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
2027
|
---|
Net sales
1 |
278.9
|
245.5
|
221.3
|
175
|
270.3
|
301
|
341.6
|
373
|
EBITDA
1 |
-205.3
|
-114.1
|
-51.05
|
-5.625
|
12.75
|
16.46
|
34.83
|
46.47
|
EBIT
1 |
-491
|
-282.8
|
-231.4
|
-158.1
|
-46.45
|
-38.37
|
1.85
|
11
|
Operating Margin
|
-176.03%
|
-115.21%
|
-104.57%
|
-90.36%
|
-17.19%
|
-12.74%
|
0.54%
|
2.95%
|
Earnings before Tax (EBT)
1 |
-3,384
|
-699.8
|
-1,720
|
-221.5
|
-59.6
|
-22.03
|
-3.68
|
-4.46
|
Net income
1 |
-3,310
|
-695.1
|
-1,718
|
-199
|
-65.58
|
-21.68
|
-5.051
|
-6
|
Net margin
|
-1,186.9%
|
-283.17%
|
-776%
|
-113.73%
|
-24.26%
|
-7.2%
|
-1.48%
|
-1.61%
|
EPS
2 |
-339.4
|
-41.00
|
-79.90
|
-6.200
|
-1.520
|
-0.4650
|
-0.1275
|
-0.1400
|
Free Cash Flow
1 |
-693
|
-263.7
|
-142.1
|
-127.8
|
-
|
-25.9
|
16.85
|
-
|
FCF margin
|
-248.46%
|
-107.41%
|
-64.18%
|
-73.03%
|
-
|
-8.6%
|
4.93%
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
48.37%
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
9/22/20
|
9/27/21
|
9/20/22
|
6/14/23
|
6/20/24
|
-
|
-
|
-
|
Fiscal Period: March |
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
2025 Q3
|
2025 Q4
|
---|
Net sales
1 |
50.43
|
50.22
|
49.26
|
61.68
|
61.68
|
64.03
|
75.11
|
63.42
|
64.42
|
67.41
|
77.57
|
70.01
|
72.78
|
78.61
|
EBITDA
1 |
-12.26
|
-12.85
|
-8.7
|
1.428
|
1.428
|
0.31
|
2.155
|
3.398
|
4.349
|
1.891
|
2.35
|
3.021
|
4.527
|
6.96
|
EBIT
|
-72.38
|
-63.9
|
-53.82
|
-71.6
|
-71.6
|
-32.68
|
-16.11
|
-11.05
|
-23.89
|
3.15
|
-
|
-
|
-
|
-
|
Operating Margin
|
-143.52%
|
-127.25%
|
-109.26%
|
-116.08%
|
-116.08%
|
-51.05%
|
-21.45%
|
-17.42%
|
-37.09%
|
4.67%
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-1,012
|
-620.1
|
-63.86
|
-67.28
|
-67.28
|
-90.39
|
-22.11
|
0.384
|
-25.28
|
-14.04
|
-4.424
|
-0.5905
|
-7.188
|
6.615
|
Net income
1 |
-1,012
|
-618.8
|
-51.6
|
-65.39
|
-67.2
|
-82
|
-26.9
|
-0.523
|
-25.56
|
-21.12
|
-6.948
|
-7.881
|
-5.477
|
-2.07
|
Net margin
|
-2,006.93%
|
-1,232.28%
|
-104.75%
|
-106.02%
|
-108.95%
|
-128.07%
|
-35.81%
|
-0.82%
|
-39.68%
|
-31.34%
|
-8.96%
|
-11.26%
|
-7.53%
|
-2.63%
|
EPS
2 |
-47.20
|
-25.90
|
-1.700
|
-2.000
|
-2.000
|
-2.500
|
-0.8000
|
-
|
-0.5000
|
-0.4100
|
-0.1300
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
5/12/22
|
9/20/22
|
11/10/22
|
2/10/23
|
2/9/23
|
6/14/23
|
8/10/23
|
11/9/23
|
2/8/24
|
6/20/24
|
-
|
-
|
-
|
-
|
Fiscal Period: March |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
2027
|
---|
Net Debt
1 |
369
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
21.9
|
211
|
73.3
|
-
|
147
|
127
|
117
|
Leverage (Debt/EBITDA)
|
-1.797
x
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-693
|
-264
|
-142
|
-128
|
-
|
-25.9
|
16.9
|
-
|
ROE (net income / shareholders' equity)
|
-11.7%
|
-12.4%
|
-11.6%
|
-
|
-
|
-5.2%
|
-3.2%
|
-1.1%
|
ROA (Net income/ Total Assets)
|
-9.21%
|
-9.65%
|
-8.46%
|
-
|
-
|
-3.7%
|
-2.2%
|
-0.8%
|
Assets
1 |
35,943
|
7,205
|
20,315
|
-
|
-
|
585.8
|
229.6
|
750
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
2 |
-34.60
|
-12.50
|
-5.110
|
-
|
-
|
0.2200
|
0.7800
|
1.190
|
Capex
1 |
355
|
53.1
|
32.2
|
12.1
|
-
|
10.3
|
11.4
|
11
|
Capex / Sales
|
127.29%
|
21.62%
|
14.55%
|
6.93%
|
-
|
3.43%
|
3.34%
|
2.95%
|
Announcement Date
|
9/22/20
|
9/27/21
|
9/20/22
|
6/14/23
|
6/20/24
|
-
|
-
|
-
|
Last Close Price
8.46
CAD Average target price
8.779
CAD Spread / Average Target +3.77% Consensus |
1st Jan change
|
Capi.
|
---|
| +9.94% | 4.81B | | -32.21% | 3.6B | | -1.43% | 3.09B | | -25.09% | 2.62B | | -11.46% | 2.27B | | +36.65% | 1.82B | | +37.15% | 1.41B | | -16.01% | 1.38B | | +40.95% | 1.37B |
Alternative Medicine
|